The case for combined chemotherapy-peptide receptor radionuclide therapy (chemo-PRRT) strategy in metastatic neuroendocrine tumor: predicting and looking at the possible case scenarios

  • Sandip BasuEmail author
  • Vikas Ostwal
Letter to the Editor

Peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE has gained substantial popularity and is typically employed in the management of grade I and Grade II metastatic neuroedocrine tumors (NETs). In routine clinics, however, the application of PRRT is frequently considered and has been extended up to a Mib1 labeling index (LI) of up to 30 %, when adequate tracer uptake is noted in the 68Ga-DOTATATE positron emission tomography–computed tomography (PET-CT) [1, 2, 3]. Combining chemotherapy with PRRT is an attractive therapeutic option for patients with relatively aggressively behaving metastatic neuroedocrine tumors (NETs) where it is unlikely to achieve favourable response to a single treatment strategy. It is thus quite important to predict and identify a priori the patients who would need this approach rather than having them follow what will be considered as a failed regimen.

Dual tracer imaging with somatostatin receptor (SSTR) targeted 68Ga-DOTA-NOC/TATE or 99mTc-HYNIC-...


Neuroendocrine tumor Peptide receptor radionuclide therapy 68Ga-DOTATATE FDG-PET/CT Chemotherapy 177Lu-DOTATATE 


Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Research involving human participants and/or animals

Not Applicable; letter to the editor.

Informed consent

Not Applicable; letter to the editor.


  1. 1.
    Öberg K, Knigge U, Kwekkeboom D, Perren A. ESMO Guidelines Working Group. Neuroendocrine gastro-entero-pancreatic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23(7):vii124–30.PubMedGoogle Scholar
  2. 2.
    Paul D, Ostwal V, Bose S, Basu S, Gupta S. Personalized treatment approach to gastroenteropancreatic neuroendocrine tumors: a medical oncologist’s perspective. Eur J Gastroenterol Hepatol. 2016;28(9):985–90.CrossRefPubMedGoogle Scholar
  3. 3.
    Basu S. Should grade of tracer uptake on somatostatin receptor-targeted imaging be the major determinant and break the barrier of histopathologic criteria for determining the suitability of Peptide receptor radionuclide therapy? J Nucl Med. 2013;54(11):2018–9.CrossRefPubMedGoogle Scholar
  4. 4.
    Basu S, Sirohi B, Shrikhande SV. Dual tracer imaging approach in assessing tumor biology and heterogeneity in neuroendocrine tumors: its correlation with tumor proliferation index and possible multifaceted implications for personalized clinical management decisions, with focus on PRRT. Eur J Nucl Med Mol Imaging. 2014;41(8):1492–6.CrossRefPubMedGoogle Scholar
  5. 5.
    Basu S, Ranade R, Thapa P. Correlation and discordance of tumour proliferation index and molecular imaging characteristics and their implications for treatment decisions and outcome pertaining to peptide receptor radionuclide therapy in patients with advanced neuroendocrine tumour: developing a personalized model. Nucl Med Commun. 2015;36(8):766–74.CrossRefPubMedGoogle Scholar
  6. 6.
    Basu S, Ranade R, Ostwal V, Shrikhande SV. PET-Based Molecular Imaging in Designing Personalized Management Strategy in Gastroenteropancreatic Neuroendocrine Tumors. PET Clin. 2016;11(3):233–41.CrossRefPubMedGoogle Scholar
  7. 7.
    Basu S, Ostwal V. Observation on enhanced avidity on somatostatin receptor targeted 68Ga-DOTATATE PET-CT following therapy with everolimus and capecitabine-temozolamide: is redifferentiation akin phenomenon a reality in neuroendocrine tumors? Nucl Med Commun. 2016;37(6):669–71.CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2016

Authors and Affiliations

  1. 1.Radiation Medicine Centre, Bhabha Atomic Research CentreTata Memorial Hospital AnnexeMumbaiIndia
  2. 2.Department of Medical OncologyTata Memorial HospitalMumbaiIndia

Personalised recommendations